Loading...
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
OBJECTIVE: In the Phase III PAOLA study (clinicaltrials.gov: NCT01137682), enrolled patients had uncontrolled acromegaly despite ≥6 months of octreotide/lanreotide treatment before study start. More patients achieved biochemical control with long-acting pasireotide versus continued treatment with oc...
Saved in:
| Published in: | Eur J Endocrinol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Bioscientifica Ltd
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7222286/ https://ncbi.nlm.nih.gov/pubmed/32217809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-19-0762 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|